Why Merck’s Big CML Bet Makes Enliven’s ELVN-001 a Takeover Star
Merck’s $6.7B acquisition of Terns Pharmaceuticals highlights huge potential in CML therapies. Why analysts see Enliven’s ELVN-001 as a best-in-class winner with strong takeover appeal.
